LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera
LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera DAEJEON, South Korea--(BUSINESS WIRE)--LegoChem Biosciences Inc. (KOSDAQ:141080) (hereinafter “LegoChemBio”) announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology company in Switzerland, to develop and commercialize a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by [...]